121 related articles for article (PubMed ID: 12410702)
1. Evaluation of a 1-h exposure time to mechlorethamine in patients undergoing topical treatment.
Foulc P; Evrard V; Dalac S; Guillot B; Delaunay M; Verret JL; Dréno B
Br J Dermatol; 2002 Nov; 147(5):926-30. PubMed ID: 12410702
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of cutaneous intolerance to topical mechlorethamine therapy in patients with cutaneous T-cell lymphomas. French Study Group of Cutaneous Lymphomas.
Estève E; Bagot M; Joly P; Souteyrand P; Beylot-Barry M; Vaillant L; Delaunay M; Avril MF; Laroche L; Grange F; Thomine E; Wechsler J
Arch Dermatol; 1999 Nov; 135(11):1349-53. PubMed ID: 10566833
[TBL] [Abstract][Full Text] [Related]
3. Clinical potential of mechlorethamine gel for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma: a review on current efficacy and safety data.
Liner K; Brown C; McGirt LY
Drug Des Devel Ther; 2018; 12():241-254. PubMed ID: 29440874
[TBL] [Abstract][Full Text] [Related]
4. Treatment of early-stage mycosis fungoides with twice-weekly applications of mechlorethamine and topical corticosteroids: a prospective study.
de Quatrebarbes J; Estève E; Bagot M; Bernard P; Beylot-Barry M; Delaunay M; D'Incan M; Souteyrand P; Vaillant L; Cordel N; Courville P; Joly P
Arch Dermatol; 2005 Sep; 141(9):1117-20. PubMed ID: 16172308
[TBL] [Abstract][Full Text] [Related]
5. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study.
Kim EJ; Geskin L; Guitart J; Querfeld C; Girardi M; Musiek A; Mink DR; Williams MJ; Angello JT; Bailey WL
J Am Acad Dermatol; 2020 Sep; 83(3):928-930. PubMed ID: 32089294
[No Abstract] [Full Text] [Related]
6. The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma.
Kim EJ; Guitart J; Querfeld C; Girardi M; Musiek A; Akilov OE; Angello JT; Bailey WL; Geskin LJ
Am J Clin Dermatol; 2021 May; 22(3):407-414. PubMed ID: 33656660
[TBL] [Abstract][Full Text] [Related]
7. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.
Lessin SR; Duvic M; Guitart J; Pandya AG; Strober BE; Olsen EA; Hull CM; Knobler EH; Rook AH; Kim EJ; Naylor MF; Adelson DM; Kimball AB; Wood GS; Sundram U; Wu H; Kim YH
JAMA Dermatol; 2013 Jan; 149(1):25-32. PubMed ID: 23069814
[TBL] [Abstract][Full Text] [Related]
8. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
Talpur R; Venkatarajan S; Duvic M
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):591-7. PubMed ID: 25068889
[TBL] [Abstract][Full Text] [Related]
9. Allergic contact dermatitis from topical carmustine.
Thomson KF; Sheehan-Dare RA; Wilkinson SM
Contact Dermatitis; 2000 Feb; 42(2):112. PubMed ID: 10703643
[No Abstract] [Full Text] [Related]
10. Topical treatment of early cutaneous T-cell lymphoma.
Ramsay DL; Meller JA; Zackheim HS
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1031-56. PubMed ID: 8522483
[TBL] [Abstract][Full Text] [Related]
11. [Can cutaneous intolerance reactions to caryolysine be prevented or controlled?].
Ann Dermatol Venereol; 1997; 124(9):662-4. PubMed ID: 9739933
[No Abstract] [Full Text] [Related]
12. In brief: mechlorethamine gel (Valchlor) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2015 Apr; 57(1467):e66. PubMed ID: 25988964
[No Abstract] [Full Text] [Related]
13. The prognostic significance of delayed hypersensitivity to dinitrochlorobenzene and mechlorethamine hydrochloride in cutaneous T cell lymphoma.
Vonderheid EC; Ekbote SK; Kerrigan K; Kalmanson JD; Van Scott EJ; Rook AH; Abrams JT
J Invest Dermatol; 1998 Jun; 110(6):946-50. PubMed ID: 9620303
[TBL] [Abstract][Full Text] [Related]
14. Current treatment of Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Online J; 2001 Feb; 7(1):3. PubMed ID: 11328624
[TBL] [Abstract][Full Text] [Related]
15. Topical mechlorethamine. Cutaneous changes in patients with mycosis fungoides after its administration.
Price NM
Arch Dermatol; 1977 Oct; 113(10):1387-9. PubMed ID: 911166
[TBL] [Abstract][Full Text] [Related]
16. Local bullous reaction to topical mechlorethamine (mustine).
Goday JJ; Aguirre A; Ratón JA; Díaz-Pérez JL
Contact Dermatitis; 1990 May; 22(5):306-7. PubMed ID: 2143454
[No Abstract] [Full Text] [Related]
17. Focal contact sensitivity to nitrogen mustard in lesions of cutaneous T-cell lymphoma (mycosis fungoides).
Shelley WB
Acta Derm Venereol; 1981; 61(2):161-4. PubMed ID: 6165197
[TBL] [Abstract][Full Text] [Related]
18. Mechlorethamine desensitization in therapy for mycosis fungoides. Topical desensitization to mechlorethamine (nitrogen mustard) contact hypersensitivity.
Constantine VS; Fuks ZY; Farber EM
Arch Dermatol; 1975 Apr; 111(4):484-8. PubMed ID: 1122150
[TBL] [Abstract][Full Text] [Related]
19. Topical nitrogen mustard for the treatment of granulomatous slack skin.
Hultgren TL; Jones D; Duvic M
Am J Clin Dermatol; 2007; 8(1):51-4. PubMed ID: 17298108
[TBL] [Abstract][Full Text] [Related]
20. Topical mechlorethamine therapy for mycosis fungoides.
Price NM; Constantine VS; Hoppe RT; Fuks ZY; Farber EM
Br J Dermatol; 1977 Nov; 97(5):547-50. PubMed ID: 588466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
